Grace Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $32.47M
- P/E (TTM)
- –
- Dividend yield
- –
About Grace Therapeutics
Pharmaceutical Preparations, SIC 2834
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. The company uses proprietary drug delivery and formulation technologies to reformulate existing pharmaceutical compounds into treatments with improved clinical outcomes, faster onset, reduced side effects, and enhanced patient compliance. Its clinical pipeline consists of three candidate products: lead candidate GTx-104, an intravenous injectable formulation of nimodipine; GTx-102, evaluated for pediatric ataxia-telangiectasia; and GTx-101, a topical spray for postherpetic neuralgia. The company’s target customer base consists of hospital healthcare systems, neurocritical intensive care units, healthcare providers, and patients suffering from rare conditions.
The company operates within the United States and evaluates market opportunities across North America, the European Union, and China, utilizing external contract research and manufacturing organizations across multiple facilities. Grace Therapeutics, Inc. maintains its principal executive offices and headquarters in Princeton, New Jersey.
Summary of the business section of Grace Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Grace Therapeutics, Inc.
- Headquarters
- Princeton, NJ
- Address
- 103 Carnegie Center, Suite 300 08540
- Phone
- (609) 322-1602
- Website
- gracetx.com
- Employees
- 5, Mar 31, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- KPMG LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- GRCE
- Exchange
- Nasdaq
- IPO date
- Feb 7, 2012
- Shares outstanding
- 21M, Aug 11, 2026
- Public float
- $35.05M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Aug 11, 2023; 1-for-6 reverse, Jul 10, 2023; 1-for-8 reverse, Nov 10, 2021; 1-for-8 reverse, Aug 31, 2021; 1-for-10 reverse, Oct 15, 2015
- SEC CIK
- 1444192
- CUSIP
- 00439U104
- ISIN
- US00439U1043
- LEI
- 529900NF00G2BB523B88
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Prashant Kohli | Chief Executive Officer, Director | 249,495 |
| Amresh Kumar | VP Program Management | 66,712 |
| Robert J. DelAversano | Principal Financial Officer | – |
| R. Loch Macdonald | Chief Medical Officer | – |
| Carrie D'Andrea | VP Clinical Operations | – |
| A. Brian Davis | Director | – |
| George Kottayil | Director | 3,462,884 |
| Vimal Kavuru | Director | 4,258,305 |
| Edward Neugeboren | Director | 37,895 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Jan DAlvise | $0 | $0 | $465.65K | $63 | – |
| FY2026 Mr Kohli | $1.27M | $1.88M | $465.65K | $63 | – |
| FY2025 Jan DAlvise | $0 | $0 | $431.91K | $31 | – |
| FY2025 Mr Kohli | $1.08M | $775.01K | $431.91K | $31 | – |
| FY2024 Jan DAlvise | $639.92K | $639.92K | $430.15K | $47 | – |
| FY2024 Mr Kohli | $997.53K | $1.23M | $430.15K | $47 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had a total of five full-time employees, all of whom are located in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 25, 2024 | Name change | Name changed from Acasti Pharma Inc. to Grace Therapeutics, Inc. |
| Jun 27, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Dec 15, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 23, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 29, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 27, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 1, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 17, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 7, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 4, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |